Compare Advance Auto Parts, Inc. (AAP) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Cytokinetics Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.22 (market cap $3.19B), while Cytokinetics Inc trades at $76.44 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 3.3× Advance Auto Parts, Inc.'s market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AAP | CYTK | |
|---|---|---|
Market Cap | $3.19B | $10.63B |
Sector | Consumer Cyclical | Technology |
52-Week High | $64.17 | $87.26 |
52-Week Low | $38.75 | $34.31 |
Enterprise Value | $5.47B | $10.74B |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.73, down 3.58% today, reflecting bearish technical signals amid mixed fundamentals. The company reported Q1 2026 EPS of $0.77, beating expectations, with revenue at $8.6 billion for 2025 but a slim net income margin of 0.51%. Recent news highlights restructuring efforts and AI-driven delivery initiatives to stabilize operations.
The outlook is cautious; while valuation ratios like P/S of 0.37 appear attractive, weak profitability and negative operating cash flow pose risks. Analyst consensus is mixed with a $61.30 price target, but high debt and competitive pressures require monitoring for sustained turnaround progress.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
